AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1434863
Drug: Patient-controlled intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled intravenous administration of morphine
Trial: 2864794
Drug: Mianserin 60
RxNorm normalized name: mianserin 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 60 mg
Trial: 29405603
Drug: Autologous umbilical
RxNorm normalized name: Autologous umbilical cord blood
DrugBank: Autologous cord blood (DB17926)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous umbilical cord blood (AUCB) infusion
Trial: 24939813
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual control condition
Trial: 20412459
Drug: Caudal levobupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal levobupivacaine 0.125% (group L)
Trial: 20412459
Drug: Caudal tramadol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal tramadol 1.5 mg.kg(‐1) (group T)
Trial: 12120807
Drug: Valerian treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valerian treatment
Trial: 9179964
Drug: Aqueous propolis
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous propolis extract NIVCRISOL administered during the cold season 1994-1995
Trial: 339438
Drug: Horse antilymphoblast
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horse antilymphoblast globulin (ALG) 20 mg/kg/day for 10 days
Trial: 339438
Drug: Human IgG
RxNorm normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Human IgG 20 mg/kg/day for 10 days (Control)
Trial: 21883874
Drug: Active PENS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active PENS therapy
Trial: 16762076
Drug: Dietary nucleotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary nucleotide supplementation (500 mg capsule three times a day for 56 days)
Trial: 16762076
Drug: Placebo (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (500 mg capsule three times a day for 56 days)
Trial: 15017564
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose cisplatin (100 mg/m2/cycle), etoposide, and bleomycin (PEB) chemotherapy for Stage I‐II patients
Trial: 15017564
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (200 mg/m2/cycle) with etoposide and bleomycin (HDPEB) for Stage III‐IV patients
Trial: 8468734
Drug: Chemotherapy (Cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (Cisplatin + 5‐Fu) and radiation
Trial: 2948826
Drug: Atrial natriuretic
RxNorm normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atrial natriuretic peptide (ANP) infusion at 1.5 pmol X kg‐1 X min‐1 for 30 min followed by 15 pmol X kg‐1 X min‐1 for a further 30 min
Trial: 2948826
Drug: Matching vehicle
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching vehicle infusions (control)
Trial: 3154686
Drug: Molsidomine (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (12 to 24 mg/day orally; initial 20 mg i.v. followed by infusion of 1 to 4 mg/hour)
Trial: 30877209
Drug: Increased treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased treatment
Trial: 30877209
Drug: Unchanged treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unchanged treatment
Trial: 30877209
Drug: Reduced treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced treatment
Trial: 30877209
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with tocilizumab for GCA and tumor necrosis factor inhibitors for TA
Trial: 29142236
Drug: Interferon-alpha (IFN-α)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN-α) therapy with a scoring model composed of miR-210, miR-22, and alanine aminotransferase (ALT)
Trial: 25441251
Drug: TLC diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLC diet with 0.5 cup of soy nuts (25 g of soy protein and 101 mg of aglycone isoflavones)
Trial: 12659385
Drug: Nebulized albuterol
RxNorm normalized name: Albuterol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized albuterol plus ipratropium
Trial: 11153621
Drug: Enteral feeding
RxNorm normalized name: enteral feeding dispenser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral feeding solution enriched with vitamins A (67 microg/dL), C (13.3 mg/dL), and E (4.94 mg/dL)
Trial: 11153621
Drug: Isocaloric and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric and isonitrogenous control solution
Trial: 9244718
Drug: TEPT-guided antiarrhythmic
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEPT-guided antiarrhythmic therapy (using flecainide, propafenone, or sotalol)
Trial: 9244718
Drug: Empiric antiarrhythmic
RxNorm normalized name: aspirin / codeine phosphate Oral Tablet [Empirin with Codeine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empiric antiarrhythmic therapy (using flecainide, propafenone, or sotalol)
Trial: 9244718
Drug: TEPT-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEPT-guided therapy
Trial: 3897351
Drug: Single vision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single vision (standard treatment) group
Trial: 31892611
Drug: 600 IUs/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 IUs/day of oral vitamin D3
Trial: 31892611
Drug: 4,000 IUs/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4,000 IUs/day of oral vitamin D3
Trial: 31892611
Drug: 10,000 IUs/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10,000 IUs/day of oral vitamin D3
Trial: 27006113
Drug: Dopamine D2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine D2 receptor antagonist (sulpiride 400 mg)
Trial: 25015680
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g of oral tyrosine
Trial: 25015680
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of oral tyrosine
Trial: 25015680
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of oral tyrosine
Trial: 25015680
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of oral tyrosine
Trial: 10808389
Drug: Celiprolol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol (200 mg)
Trial: 7210690
Drug: No administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No administration of Oxazepam
Trial: 28859993
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin (gel)
Trial: 28859993
Drug: Topical ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical ciprofloxacin (other formulations)
Trial: 26081567
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa targeting hemoglobin (Hb) levels of 11-13 g/dL
Trial: 26081567
Drug: Low Hb
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Hb group maintained at 9.0-11.0 g/dL using epoetin alfa
Trial: 24614074
Drug: Naso-gastric infusion
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naso-gastric infusion of chocolate milk (stomach distention + nutrients)
Trial: 24614074
Drug: Naso-gastric infusion
RxNorm normalized name: gastric mucins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naso-gastric infusion of water (stomach distention)
Trial: 24614074
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of chocolate milk (stomach distention + nutrients + oral exposure)
Trial: 20527136
Drug: 85% formic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 85% formic acid in distilled water solution
Trial: 16272420
Drug: Telephone mode
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone mode of G-CAHPS survey
Trial: 16272420
Drug: Mail mode
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mail mode of G-CAHPS survey
Trial: 11906502
Drug: Ciprofloxacin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (500 mg single dose)
Trial: 11906502
Drug: Norfloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (400 mg twice daily for 3 days)
Trial: 9759984
Drug: Captopril (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (25 mg twice daily for 3 months)
Trial: 7799050
Drug: Calcium mupirocin
RxNorm normalized name: Mupirocin Calcium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium mupirocin ointment administered intranasally for five days
Trial: 3197372
Drug: Local nervous
RxNorm normalized name: Syzygium nervosum flower bud extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local nervous blockade (lignocaine 3.7 x 10(‐4)‐7.4 x 10(‐2) mol/l)
Trial: 28457980
Drug: Fresh Frozen
RxNorm normalized name: Fresh frozen plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fresh Frozen Plasma (FFP) 15 mL/kg of bodyweight
Trial: 28457980
Drug: Coagulation Factor
RxNorm normalized name: Coagulation factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coagulation Factor Concentrates (CFC) primarily fibrinogen concentrate 50 mg/kg of bodyweight
Trial: 21263100
Drug: Biweekly intravenous
RxNorm normalized name: Biweekly Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biweekly intravenous dactinomycin 1.25 mg/m²
Trial: 21263100
Drug: Weekly intramuscular
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly intramuscular (IM) methotrexate 30 mg/m²
Trial: 15042325
Drug: 18F-desmethoxyfallypride (18F-DMFP)
RxNorm normalized name: (18F)-Fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-desmethoxyfallypride (18F-DMFP) PET imaging after injection of 180-200 MBq
Trial: 9126305
Drug: 5'-DFUR (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5'-DFUR (mean 9,000 mg) preoperatively
Trial: 9126305
Drug: No anticancer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anticancer agents (Control group B)
Trial: 7984719
Drug: Popping air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Popping air capsules for 5 minutes (experimental group)
Trial: 24274771
Drug: Cocoa treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa treatment (37 g/d of dark chocolate and a sugar-free cocoa beverage, total cocoa = 22 g/d, total flavanols = 814 mg/d)
Trial: 24274771
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (low-flavanol chocolate bar and a cocoa-free beverage, total flavanols = 3 mg/d)
Trial: 19064532
Drug: Cocoa treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa treatment
Trial: 22170713
Drug: Intensive glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive glycemic control (IGC; n=20; glucose goal, 80‐140 mg/dl)
Trial: 22170713
Drug: Conventional glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional glycemic control (CGC; n=20; glucose goal, 180‐200 mg/dl)
Trial: 22170713
Drug: Glucose-insulin-potassium (GIK;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium (GIK; n=10; glucose goal, 180‐200 mg/dl)
Trial: 22170713
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (25 patients with glycemia below 140 mg/dl)
Trial: 17505990
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of famotidine (10 mg) and omeprazole (20 mg)
Trial: 11796648
Drug: Famotidine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (10 mg)
Trial: 16173416
Drug: ROM regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROM regimen (one-dose regimen)
Trial: 10520779
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg daily for 4 weeks
Trial: 2502950
Drug: Topical mupirocin
RxNorm normalized name: mupirocin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mupirocin applied three times daily
Trial: 2502950
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin ethylsuccinate (30 to 50 mg/kg per day)
Trial: 852890
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg pivampicillin tablets
Trial: 852890
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg pivampicillin tablets (fasting)
Trial: 852890
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg pivampicillin tablets (non-fasting)
Trial: 30727810
Drug: Behavioral medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral medicine approach to physical therapy (BMPI)
Trial: 20488431
Drug: bepotastine besilate
RxNorm normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bepotastine besilate ophthalmic solution 1.0%
Trial: 20488431
Drug: bepotastine besilate
RxNorm normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bepotastine besilate ophthalmic solution 1.5%
Trial: 19843481
Drug: bepotastine besilate
RxNorm normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bepotastine besilate ophthalmic solution 1.0% and 1.5%
Trial: 3298412
Drug: human lymphoblastoid
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: human lymphoblastoid interferon (Wellferon) given for 28 consecutive days at a dosage ranging from 2.5 to 7.5 MU/m2 i.m.
Trial: 23860273
Drug: TY-51924 (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TY-51924 (up to 30 mg/kg)
Trial: 22439653
Drug: Intensive smoking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive smoking cessation counselling (face-to-face visits weekly for the first four weeks, monthly to six months, and two monthly to 12 months) and encouragement to attend a monthly smoking cessation support group.
Trial: 18678295
Drug: High-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose clopidogrel (600 mg loading immediately before PCI and 75 mg 2 times/day for 1 month)
Trial: 18678295
Drug: Standard-dose clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose clopidogrel (300 mg loading and 75 mg/day)
Trial: 15620444
Drug: Gentamicin-collagen implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin-collagen implant
Trial: 15620444
Drug: Control (routine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (routine intravenous antimicrobial prophylaxis)
Trial: 10379218
Drug: Antibiotic prophylaxis
RxNorm normalized name: STONE PROPHYLAXIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic prophylaxis (trimethoprim TMP‐SMZ, nitrofurantoin, or a quinolone)
Trial: 10379218
Drug: Intermittent patient‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent patient‐administered treatment (taken at the onset of symptoms)
Trial: 2058162
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (8 capsules Ameu per day) for 21 days
Trial: 2058162
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (8 capsules Ameu per day) for 56 days
Trial: 26565005
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg lovastatin for 5 days
Trial: 17718820
Drug: Intrathecal baclofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal baclofen (ITB) at doses of 12.5 microg, 20 microg, 25 microg, and 50 microg.
Trial: 15733401
Drug: Standard heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard heparin (n = 37)
Trial: 15733401
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (n = 31)
Trial: 7886187
Drug: Alcohol (0.83
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.83 ml ethanol/kg body weight)
Trial: 2838344
Drug: Clofazimine (0.01‐5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofazimine (0.01‐5 micrograms/ml)
Trial: 30158072
Drug: Amlodipine-based treatment
RxNorm normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine-based treatment
Trial: 10512261
Drug: Midazolam 1
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 1 mg IV and meperidine 50 mg
Trial: 10512261
Drug: Ro 48-6791
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 48-6791 0.5 mg IV and meperidine 50 mg
Trial: 10512261
Drug: Ro 48-6791
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 48-6791 1.0 mg IV alone
Trial: 10512261
Drug: Ro 48-6791
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 48-6791 (both doses)
Trial: 7717282
Drug: Digoxin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digoxin (0.25 mg once daily)
Trial: 6988170
Drug: Cefuroxime (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime (1.5 g by intravenous injection prior to induction of anaesthesia)
Trial: 28554517
Drug: Collagenase clostridium
RxNorm normalized name: Collagenase Clostridium Histolyticum
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Collagenase clostridium histolyticum injection
Trial: 22040192
Drug: Sertraline (25-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (25-150 mg/day)
Trial: 20127533
Drug: 40 mL
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mL of 0.25% levobupivacaine (LB group)
Trial: 10473477
Drug: Drug counselling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug counselling
Trial: 10473477
Drug: Treatment leaflets
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment leaflets
Trial: 10473477
Drug: Counselling for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselling for patients with major depressive disorder receiving doses >=75 mg
Trial: 10473477
Drug: No counselling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No counselling for patients with major depressive disorder receiving doses >=75 mg
Trial: 8758157
Drug: Intramuscular bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular bupivacaine 12.5 mg
Trial: 6918920
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation at 2 liters per minute for 30 minutes
Trial: 6918920
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation at 4 liters per minute for 30 minutes
Trial: 6918920
Drug: Oxygen inhalation
RxNorm normalized name: oxygen INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen inhalation at 6 liters per minute for 30 minutes
Trial: 6918920
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no oxygen inhalation)
Trial: 30782008
Drug: DVD intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DVD intervention (the Sleep Easy Solution)
Trial: 28448664
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg intravitreous bevacizumab
Trial: 28448664
Drug: 0.125 mg
RxNorm normalized name: digoxin 0.125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125 mg intravitreous bevacizumab
Trial: 28448664
Drug: 0.063 mg
RxNorm normalized name: benzocaine 0.063 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.063 mg intravitreous bevacizumab
Trial: 28448664
Drug: 0.031 mg
RxNorm normalized name: camphor 0.031 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.031 mg intravitreous bevacizumab